Estrada-Aguilar L, Amaya-Guerra M, Gómez-Flores M, Guevara-Sanginés E, Jurado-Santacruz F, Lopeztello- Santillán A, Maldonado-García C, Rivera-Gómez M, Rodríguez-Martínez N, Vega-González L

Language: Spanish
References: 17
Page: 90-97
PDF size: 269.20 Kb.

ABSTRACT

Psoriasis is a chronic inflammatory disease with a worldwide prevalence between 6 and 39% in moderate to severe forms.
In European countries like Germany and England was identified that only one third of patients with moderate to severe forms will receive systemic management, this fact motivated to integrate into Europe an international consensus on treatment goals with the aim of providing support to the dermatologist by algorithms that serve as a therapeutic guide that allows you to gain control short and long term effects of this disease.
The European group met to develop the definitions of severity of psoriasis, treatment goals for moderate to severe disease, and optimization options and / or therapeutic transition than a paper published in 2011 was obtained.
In Mexico a working group of experts on biological therapy (GTEB), made up of 10 members and an extended group of 150 dermatologists’ voters in the country for the purpose of issuing Mexico’s position on the proposals of the European group was formed.
In this document the findings of the Working Group of Experts on Biological Therapy in Mexico are listed.

REFERENCES

1. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom. Arch Dermatol. 2005;141:1537-41.

2. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: Results from a population-based study. J Am Acad Dermatol. 2005;52:23-6.

3. Falk ES, Vandbakk O. Prevalence of psoriasis in a Norwegian Lapp population. Acta Derm Venereol Suppl (Stockh). 1993;182:6-9.

4. Barisic-Drusko V, Paljan D, Kansky A, Vujasinovic S. Prevalence of psoriasis in Croatia. Acta Derm Venereol Suppl (Stockh). 1989;146:178-9.

5. Braathen LR, Botten G, Bjerkedal T. Prevalence of psoriasis in Norway. Acta Derm Venereol Suppl (Stockh). 1989;142:5-8.

6. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm Venereol. 1981;61:344-6.

7. Chang YT, Chen TJ, Liu PC, Chen YC, Chen YJ, Huang YL, et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol. 2009;89:262-6.

8. Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, et al. Prevalence of psoriasis in China: A population-based study in six cities. Eur J Dermatol. 2012;22:663-7.

9. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60:218-24.

10. Nestle F, Kaplan D, Barker J. Mechanisms of disease Psoriasis. N Eng J Med. 2009;361:496-509.

11. Mrowietz U, Kragballe K, Reich K et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10.

12. Centro Nacional de Excelencia Tecnológica en Salud. Guía de práctica clínica: Tratamiento farmacológico para pacientes adultos con psoriasis en placas. México: Secretaría de Salud; 2013.

13. Varela-Ruiz M. Descripción y usos del método Delphi en investigaciones del área de la salud. Inv Ed Med. 2012;1(2):90-95.

14. Schafer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol. 2010;20:62-7.

15. Kimball AB, Krueger GG, Woolley JM. The Dermatology Life Quality Index (DLQI) provides qualitatively different information from the PASI. J Am Acad Dermatol. 2004;50:P156.

16. Augustin M, Kruger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008;216:366-72.

17. Finlay AY. Current severe psoriasis and the rules of tens. Br J Dermatol. 2005;152:861-7.